Welcome to our dedicated page for Health Catalyst SEC filings (Ticker: HCAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Health Catalyst's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Health Catalyst's regulatory disclosures and financial reporting.
Health Catalyst, Inc. CEO Albert Benjamin reported equity compensation and a related tax-withholding share sale. On February 25, 2026, he received 930,000 restricted stock units (RSUs) and 38,833 performance-based RSUs (PRSUs), each convertible into one common share if vesting conditions are met.
Under the company’s 2019 Stock Option and Incentive Plan, 16.67% of the RSUs vest on March 1, 2026, with the remaining 83.33% vesting in 10 equal quarterly installments. The PRSUs were granted based on performance criteria for the fiscal year ended December 31, 2025.
On February 26, 2026, Benjamin disposed of 13,304 common shares at $1.7478 per share to satisfy tax withholding obligations from vested RSUs. The company describes this as a mandatory "sell to cover" transaction rather than a discretionary trade.
Health Catalyst, Inc. Chief People Officer Linda Llewelyn reported equity compensation and related tax withholding transactions in company common stock. She received a grant of 191,500 restricted stock units (RSUs), each representing one share, which will vest in 12 equal quarterly installments beginning on March 1, 2026.
She was also credited with 13,195 performance-based restricted stock units (PRSUs) tied to the company’s performance for the fiscal year ended December 31, 2025. Separately, 4,471 shares were disposed of at $1.7478 per share to cover tax withholding obligations in connection with RSU vesting, under a mandated "sell to cover" election, and not as a discretionary trade. After these transactions, she directly owned 343,487 shares of common stock.
Health Catalyst, Inc. General Counsel Benjamin Landry reported stock-based compensation and a related tax sale of common stock. On February 25, 2026, he received an award of 289,000 restricted stock units (RSUs) that will vest in 12 equal quarterly installments beginning on March 1, 2026, each RSU converting into one share of common stock when vested.
He was also granted 16,473 performance-based restricted stock units (PRSUs) tied to performance criteria for the fiscal year ended December 31, 2025. On February 26, 2026, 6,317 shares were disposed of at $1.7478 per share to cover tax withholding obligations from vesting RSUs, a mandated “sell-to-cover” under the company’s equity plans rather than a discretionary trade. After these transactions, he directly owned 399,156 shares of common stock.
Health Catalyst, Inc. Chief Financial Officer Jason Alger reported equity compensation awards and an automatic tax-related share sale. On February 25, 2026, he received 507,500 restricted stock units (RSUs) and 22,222 performance-based RSUs under the company’s 2019 Stock Option and Incentive Plan.
Each RSU and PRSU represents a right to receive one share of common stock, with the RSUs vesting in 12 equal quarterly installments beginning on March 1, 2026 and the PRSUs tied to performance for the fiscal year ended December 31, 2025. On February 26, 2026, 7,522 shares were disposed of at $1.7478 per share solely to cover tax withholding obligations in a mandatory “sell to cover” transaction, which the filing states was not a discretionary trade by Alger. Following these transactions, he held 768,614 shares of common stock directly.
Health Catalyst, Inc. Form 144 reports a proposed sale of 6,317 restricted common shares and discloses recent restricted-stock dispositions by Benjamin Landry of 14,387 and 27,425 shares. The filing names Morgan Stanley Smith Barney LLC as the broker and lists 02/26/2026 as the sale date for the planned transaction.
Health Catalyst insider sale notice. A Form 144 filing dated 02/26/2026 indicates a proposed sale of 6,614 shares of common stock (restricted stock) of Health Catalyst, Inc. through Morgan Stanley Smith Barney LLC. The filing also discloses prior sales of 16,401 shares on 12/01/2025 for $47,566.18.
Health Catalyst, Inc. sale notice lists 4,471 shares of common stock proposed to be sold through Morgan Stanley Smith Barney LLC.
The filing shows 9,762 shares of restricted stock were sold in the past three months and that shares outstanding were 70,730,884 as of 02/26/2026. The securities are identified as restricted stock issued for compensation.
Health Catalyst, Inc. filing a Form 144 discloses a proposed sale of 7,522 restricted shares of common stock on 02/26/2026 under a compensation-related plan. The excerpt also shows a prior sale on 12/01/2025 of 20,619 restricted shares by the same reporting address.
Health Catalyst, Inc. filing notifies a proposed sale of 28,875 restricted common shares to be sold on 02/26/2026. The sale is listed as compensation stock and identifies Morgan Stanley Smith Barney LLC at 1 New York Plaza as the broker.
The filing names Daniel Burton and shows prior restricted stock sales of 55,715 shares on 12/01/2025 for $161,584.64. Shares outstanding are listed as 70,730,884 as of 02/26/2026.